Ivarmacitinib for Atopic Dermatitis Not Improved by Other Treatments
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medication called ivarmacitinib for people with moderate-to-severe atopic dermatitis (severe itchy, inflamed skin) who haven't seen enough improvement from other similar treatments. Researchers want to see if switching to this new drug helps control symptoms better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You have moderate-to-severe atopic dermatitis and have been treated with IL-4Rα inhibitor medications (like dupilumab) for at least 12 weeks
- Your skin disease is not well controlled: either your eczema affects a large area of your body or your itching is still severe
- You have no serious heart, liver, or kidney disease
- You have no active infections requiring antibiotics or antivirals, and no tuberculosis or hepatitis
- You are not pregnant, not breastfeeding, and willing to use birth control if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication (Ivarmacitinib) for people aged 12–75 with moderate-to-severe atopic dermatitis (a chronic skin condition causing red, itchy skin). The goal is to see if it improves symptoms safely in both adolescents and adults.
This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.
This trial tests a once-daily pill called Ivarmacitinib (a JAK inhibitor) taken alone to see if it can improve symptoms in people with rheumatoid arthritis who have not responded well to standard treatments like methotrexate. The study aims to find a more effective option for those who need better control of their RA.
This trial tests a drug called Ivarmacitinib for people whose solid tumors stopped responding to immunotherapy due to side effects. It aims to see if Ivarmacitinib can help control the tumor while managing those side effects.
This trial tests a new daily pill, ivarmacitinib, for people with polymyalgia rheumatica (PMR). It may help control symptoms without needing steroids long-term.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.